Keryx Biopharmaceuticals, Inc. Announces Appointment of Daniel P. Regan to
Board of Directors
Former Global General Manager, Senior Vice President of the Renal Franchise at
Genzyme (Sanofi) Brings Key Renal Commercialization Expertise to Keryx
NEW YORK, Oct. 4, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX) today announced the appointment of Daniel P. Regan to the
Company's Board of Directors.
Daniel P. Regan, 49, joins the Keryx Board of Directors with broad
pharmaceutical leadership experience across the spectrum of global
commercialization, sales and marketing of novel therapies for the treatment of
patients with chronic kidney disease. From 1999 to 2011, Mr. Regan held
positions of increasing responsibility at Genzyme/Sanofi (NYSE:SNY) leading
multi-functional teams in sales, marketing and commercialization of the renal
products. Mr. Regan's career at Genzyme included his appointment as Global
General Manager, Senior Vice President of the Renal franchise, where he was
directly responsible for all aspects of worldwide renal commercial operations,
including the Renagel^®/Renvela^® phosphate binder franchise and the worldwide
launch of Renvela^®, growing the renal franchise to global revenue approaching
$1 billion. Mr. Regan is currently Chief Commercial Officer of Intercept
Pharmaceuticals (Nasdaq:ICPT). From 2011 to 2012, Mr. Regan served as Chief
Commercial Officer of Inspiration Biopharmaceuticals, which sold its main
asset to Baxter International. Mr. Regan has a B.A. degree in Economics from
the University of Massachusetts.
"We are extremely excited to have Dan Regan join our board of directors," said
Ron Bentsur, the Company's Chief Executive Officer. "Dan brings forth
tremendous commercialization experience and a wealth of knowledge in the renal
space.We look forward to leveraging his expertise towards the potential
launch of Zerenex^TM (ferric citrate coordination complex), our drug candidate
for the treatment of hyperphosphatemia in dialysis patients."
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate
coordination complex), an oral, ferric iron-based compound that has the
capacity to bind to phosphate and form non-absorbable complexes. Keryx has
completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment
of hyperphosphatemia (elevated phosphate levels) in patients with chronic
kidney disease on dialysis, conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the Food and Drug Administration (FDA), and
the Company has submitted a New Drug Application to the FDA.The Marketing
Authorization Application filing with the European Medicines Agency (EMA) is
pending submission.Zerenex is also in Phase 2 development in the U.S. for the
management of phosphorus and iron deficiency in anemic patients with Stages 3
to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's
Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has
filed its New Drug Application for marketing approval of ferric citrate in
Japan for the treatment of hyperphosphatemia in patients with chronic kidney
disease. Keryx is headquartered in New York City.
Some of the statements included in this press release, particularly those
relating to the commercial opportunity, competitive positioning, and business
prospects for Zerenex, may be forward-looking statements that involve a number
of risks and uncertainties. For those statements, we claim the protection of
the safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially are the following: the risk that the
NDA and MAA will not be accepted for review by the FDA and EMA, respectively,
due to deficiencies in the application or for other reasons; the risk that the
FDA and EMA ultimately deny approval of the NDA and MAA, respectively; the
risk that SPAs are not a guarantee that the FDA will accept an NDA for filing
or ultimately approve a product candidate following submission; whether the
FDA and EMA will concur with our interpretation of our Phase 3 study results
or the conduct of the study; whether Zerenex, if approved, will be
successfully launched and marketed; and other risk factors identified from
time to time in our reports filed with the Securities and Exchange Commission.
Any forward-looking statements set forth in this press release speak only as
of the date of this press release. We do not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. This press release and prior releases are available at
http://www.keryx.com. The information found on our website is not incorporated
by reference into this press release and is included for reference purposes
CONTACT: Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.